Real-life data of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in the patients with chronic hepatitis B: a single-center experience

Background & Aims: Chronic hepatitis B (CHB) infection can cause liver cirrhosis and hepatocellular carcinoma. In this study, it was aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) alafenamide (TAF) on clinical parameters, glomerular filtration rate (GFR), phosphorus metabolism in patients with CHB. 
 Materials Methods: Eighty-one CHB treated TDF were included study. 27 them switched from TAF during follow-up considered as group. 54 continued evaluated Demographic, clinical, laboratory data obtained outpatient files.
 Results: The mean ages 45±12 48±15 groups, respectively. durations treatment 31±20 52±32 months, duration use significantly higher group (0.01). aspartate aminotransferase (AST), alanine (ALT), GFR, serum levels before/after 48/23 U/L, 67/25 99/103 ml/min, 2.9/3.1 mg/dl group, AST, ALT, before treatment/at time switch/after 42/22/21 48/23/22 90/100/102 2.8/2.3/2.9 Decrease values transaminases after both groups increase level switching found significant (p